NCT01467180View on ClinicalTrials.gov

Myoglobin Removal by High Cut-off CVVHD

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
RhabdomyolysisRenal Failure
Interventions
DEVICE

septeX

continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h

DEVICE

HF CVVH

continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h

Trial Locations (1)

60590

Klinik für Anästhesiologie, Intensivmedizin, Uni-Klinikum, Frankfurt am Main

All Listed Sponsors
collaborator

Gambro Dialysatoren GmbH

INDUSTRY

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

Vantive Health LLC

INDUSTRY

NCT01467180 - Myoglobin Removal by High Cut-off CVVHD | Biotech Hunter | Biotech Hunter